Your search for dabigatran returned 116 results

Your search for dabigatran returned 116 results

Sort Results:

Relevant Recent

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
Drug Monograph Updates

June 2014 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June. The chart below provides highlights of key monograph updates made this month (not an inclusive list).
Drugs in the Pipeline

FDA Accepts sNDA for New Pradaxa Indication

Boehringer Ingelheim announced that the FDA has accepted for filing the supplemental New Drug Application (sNDA) for Pradaxa (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have had primary elective total hip replacement surgery.

FDA Updates on Bleeding Risk of Pradaxa

The FDA's recommendations regarding Pradaxa remain unchanged following the November 2012 Mini-Sentinel evaluations. Findings showed that bleeding rates associated with Pradaxa use during the period did not appear to be higher than those associated with warfarin.
Clinical Charts

High-Alert Medications

High-Alert Medications according to ISMP guidelines